Evercore ISI Reiterates Buy Rating on Revolution Medicines, Inc.
Evercore ISI Group maintains a buy rating on Revolution Medicines, Inc. with a $220 price target.
Key Points
- Evercore ISI Group reiterated its buy rating on Revolution Medicines, Inc. (NasdaqGS:RVMD) with a $220 price target on June 10, 2026.
- Shares of Revolution Medicines traded near $153.87, with a market cap of approximately $32.71 billion and a forward P/E of -27.
- Other analysts, including RBC Capital and HC Wainwright & Co., also maintain buy ratings, with targets of $182 and $195, respectively.
Revolution Medicines, Inc. (NasdaqGS:RVMD) received a reaffirmation of confidence from Evercore ISI Group, which reiterated its buy rating on the stock with a price target of $220. Analyst Cory Kasimov made this call on June 10, 2026, as the stock traded around $153.87.
Other Institutional Activity in Revolution Medicines
Farallon Capital Management LLC trimmed its holdings by 978,000 shares, leaving it with about 13.6 million shares worth $1.32 billion. Meanwhile, BlackRock, Inc. boosted its position by 2,286,050 shares, holding approximately 11.2 million shares valued at $1.09 billion. Janus Henderson Group PLC reduced its stake by 2,537,006 shares, now holding about 9.8 million shares valued at $949.5 million. Baker Bros. Advisors LP added 100,000 shares, ending with roughly 9.6 million shares worth $929.3 million.
Revolution Medicines, Inc. Stock Snapshot
Shares of Revolution Medicines traded at approximately $153.87. The company has a market cap of about $32.71 billion. It carries a forward P/E ratio of -27, indicating it isn't currently profitable. The stock's beta is 1.407, suggesting higher volatility compared to the market. Over the past year, the stock has ranged from $34.00 to $166.50, with a 50-day moving average of $141.50 and a 200-day moving average of $92.76.
Analysts Set New Price Targets
On June 10, 2026, Evercore ISI Group maintained its buy rating on Revolution Medicines with a $220 price target. Other analysts like RBC Capital and HC Wainwright & Co. also kept their buy ratings, setting targets at $182 and $195, respectively. The consensus among 21 analysts is a strong buy, with an average price target of $187.29.
About Revolution Medicines, Inc.
Revolution Medicines, Inc. is a biotechnology company based in Redwood City, California, focusing on precision oncology. It develops targeted therapies for cancers driven by RAS proteins. The company, led by CEO Dr. Mark A. Goldsmith, has a pipeline of RAS(ON) inhibitors and companion inhibitors designed to treat RAS-addicted cancers.
Bottom Line
Evercore ISI Group's reaffirmation of its buy rating on Revolution Medicines, Inc. underscores ongoing confidence in the company's strategic direction and potential. As the stock trades at $153.87, investors are keeping a close watch on its performance. Remember, 13F filings and analyst ratings are backward-looking snapshots, reflecting past positions and outlooks.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.